Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Karri A Bauer"'
Autor:
Karri A. Bauer, Laura A. Puzniak, Kalvin C. Yu, Kenneth P. Klinker, Janet A. Watts, Pamela A. Moise, Lyn Finelli, Vikas Gupta
Publikováno v:
BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Antibiotic usage and antibiotic resistance (ABR) patterns changed during the COVID-19 pandemic. Inadequate empiric antibiotic therapy (IET) is a significant public health problem and contributes to ABR. We evaluated factors associ
Externí odkaz:
https://doaj.org/article/bd79a4f4ac744a1ab3a466f90d277b7c
Publikováno v:
BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Excessive use of antibiotics has been reported during the SARS-CoV-2 pandemic. We evaluated trends in antibiotic use and culture positive Gram-negative (GN)/Gram-positive (GP) pathogens in US hospitalized patients before and durin
Externí odkaz:
https://doaj.org/article/dc22b52b6dfd4b6980821c8ba0468179
Autor:
Karri A. Bauer, Laura A. Puzniak, Kalvin C. Yu, Lyn Finelli, Pamela Moise, ChinEn Ai, Janet A. Watts, Vikas Gupta
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Bloodstream infections (BSIs) are an important cause of morbidity and mortality in hospitalized patients. We evaluate incidence of community- and hospital-onset BSI rates and outcomes before and during the SARS-CoV-2 pandemic. Met
Externí odkaz:
https://doaj.org/article/7d707de5abbc43ccaf55dccc20eb8795
Autor:
Laura Puzniak, Lyn Finelli, Kalvin C. Yu, Karri A. Bauer, Pamela Moise, Carisa De Anda, Latha Vankeepuram, Aryana Sepassi, Vikas Gupta
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Past respiratory viral epidemics suggest that bacterial infections impact clinical outcomes. There is minimal information on potential co-pathogens in patients with coronavirus disease-2019 (COVID-19) in the US. We analyzed pathog
Externí odkaz:
https://doaj.org/article/c4c44d0337a14195910d5db541cdb0f7
Autor:
Kenneth P. Klinker, Levita K. Hidayat, C. Andrew DeRyke, Daryl D. DePestel, Mary Motyl, Karri A. Bauer
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 8 (2021)
The rapid evolution of resistance, particularly among Gram-negative bacteria, requires appropriate identification of patients at risk followed by administration of appropriate empiric antibiotic therapy. A primary tenet of antimicrobial stewardship p
Externí odkaz:
https://doaj.org/article/812fbac324e34437ad7980173a439e12
Autor:
Kenneth P. Klinker, Levita K. Hidayat, Eric Wenzler, Joan-Miquel Balada-Llasat, Mary Motyl, C. Andrew DeRyke, Karri A. Bauer
Publikováno v:
Antibiotics, Vol 11, Iss 5, p 660 (2022)
Antimicrobial resistance is a global public health threat, and gram-negative bacteria, such as Enterobacterales and Pseudomonas aeruginosa, are particularly problematic with difficult-to-treat resistance phenotypes. To reduce morbidity and mortality,
Externí odkaz:
https://doaj.org/article/8c31b56bde1d4b6386b74318a37f5b6c
Autor:
Karri A. Bauer, Kalvin Yu, Pamela A. Moise, Lyn Finelli, ChinEn Ai, Janet Watts, Gang Ye, Vikas Gupta
Publikováno v:
Mycoses. 66:483-487
Autor:
Sibylle Lob, Meredith Hackel, Fakhar Siddiqui, Karri A Bauer, Charles A DeRyke, Katherine Young, Mary Motyl, Daniel F Sahm
Publikováno v:
Open Forum Infectious Diseases. 9
Background Antimicrobial resistance of P. aeruginosa to commonly used β-lactams is typically higher in isolates collected from ICU patients and those with hospital-acquired infections. P. aeruginosa with multidrug-resistance (MDR) or difficult-to-tr
Autor:
Sibylle Lob, Meredith Hackel, Fakhar Siddiqui, Karri A Bauer, Charles A DeRyke, Katherine Young, Mary Motyl, Daniel F Sahm
Publikováno v:
Open Forum Infectious Diseases. 9
Background Gram-negative pathogens with multidrug resistance (MDR) or difficult-to-treat resistance (DTR) are increasingly common, resulting in limited treatment options. These resistant pathogens are often isolated from the respiratory tract or bloo
Autor:
Karri A Bauer, Laura A Puzniak, Kalvin C Yu, Kenneth P Klinker, Janet A Watts, Pamela A Moise, Lyn Finelli, ChinEn Ai, Vikas Gupta
Publikováno v:
Open forum infectious diseases. 9(11)
Background Antibacterial therapy is frequently used in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) without evidence of bacterial infection, prompting concerns about increased antimicrobial resistance (AMR). We evaluated